Member Info for SamJSung

Very interesting .. reported at 16:26... executed at 14:26 was (I believe) a 100K purchase of SNG shares...The last purchase of 100K shares in one block was on the 22nd Jan 2018 at 11.5p... against the 13.75p per share paid today.. There are a few very strong believers out there.. and willing to back their belief in SNG with deep pockets... A very positive sign that a bright future for SNG is ahead...

Southampton, UK - 7 February 2018: Synairgen (LSE: SNG), the respiratory drug discovery and development company, today announces that the first patients have been dosed in the Company's Phase II trial of inhaled SNG001 in patients with chronic obstructive pulmonary disease (COPD).

The second key event will be the mid‐year read out from the phase 1 studies that are underway on the two lead candidates from our anti fibrotic LOXL2 program. Our decision late last year to take full scientific and commercial control of the collaboration with UK biotech Synairgen was driven by our increasing confidence in this program and the very high level of interest we are receiving from the large Pharmaceutical companies that are active in the liver and lung fibrosis markets.��We have used some of the cash that the BI deal has provided to substantially increase our interest in the commercial returns from the program in exchange for a one‐off payment to Synairgen. The end of phase 1 is not a classic major value inflection point for a new drug given that you have shown safety in healthy volunteers but not yet any efficacy in patients with the disease being targeted.��Despite this I believe that this point in our LOXL2 program is significant from a valuation perspective. There are very few anti fibrotic drugs under development and the number of companies chasing a good asset is high.��This means that companies are looking earlier and earlier in the development pipeline of biotechs to identify promising drugs to add to their development portfolio.�� I met with many of these companies at the JP Morgan conference in San Francisco earlier this month and several are already investing considerable resources in doing due diligence on our science whilst the phase 1 studies are ongoing.��I anticipate that a major deal in the second half of this year will be our reward if the phase 1 studies are successful.

The rediculous and over generous Pay for the senior executives of Carillion was overseen by:-Alison Horner The chair of the remuneration committee, which sets the Carillion pay policy and made the over generous change to Senior Executive Remuneration, is the non-executive Carillion director Alison Horner, head of human resources at Tesco. Tesco should be seriously considering replacing this individual and quickly..

Has it occured to others why Pharmaxis did not bid for SNG as a means of achieving 100% ownership of the LOXL2 Programme ? or was there an attempt to do so before signing the latest agreement with SNG to share revenues... Might the large shareholders have been (quite rightly ) demanding a price substantially in excess of the current share price ? Might Pharmaxis be a future bidder of SNG if all goes well with its Phase 1 / Partnership agreements... And be able to add SNG's COPD potential blockbuster to its portfolio ?

800000 shares bought at 16.82 p at 16:42....somebody likes this share ( a lot)

Would it not have been in both parties interest to have either merged or for for a takeover of Synairgen by Pharmaxis to obtain 100% of the LOXL2 rights.. Does this arrangement with Pharmaxis now makw SNG a Cash Shell with a very limited pipeline and a ready candidate for either a merger or takeover with a larger company...especially one interested in COPD and related areas ?

16:31 Today ...SNG RNS details Richard Griffiths has further increased his stake in SNG from 13.95% to 14.68%.. (13,416,112 shares he now owns) His faith in SNG delivering is being matched by his pocket.

Richard Marsden Presentation at yesterdays Proactive Investors One2One Investor Forum - London.. http://www.synairgen.com/media/1360/synairgen-interim-results-presentation-27-september-2017.pdf Richard appears to have made a very positive impression.... SNG's share price up 5.8% at 13.75p... The future for SNG is looking very bright indeed...

I suspect the lessons learned from the Astra trial are being put into practice... see below from SNG Press release dated 27th Sept... First, studies in COPD patients published in 2017 suggest that, looking at all colds in the study period, the risk that a cold will cause an exacerbation of COPD is around 50%2 and could be even higher in particular at risk patients3 , making COPD a very attractive market. The exacerbation rate in the INEXAS and Aviragen trials in asthma was below 10%. Secondly, a novel point of care diagnostic tool has been developed which enables rapid confirmation of the existence of a respiratory viral infection when patients present themselves at the hospital or trial site. This enables us to treat only those patients who are infected with a virus, significantly reducing the number of subjects required to show the potential effect of SNG001. Clearly this has significant benefits in the future, allowing accurate prescribing of an anti-viral therapy quickly to those patients who could benefit from treatment. Synairgen�s strategy for its wholly-owned SNG001 programme is to progress into clinical development in COPD. The Company has therefore designed a short trial for the winter of 2017/18 to evaluate the potential of SNG001 in COPD, which is being submitted for regulatory approval

Proactive Investors One2One Investor Forum - London Synairgen plc Nov 2nd 2017, 6.00 pm - Chesterfield Mayfair Hotel, 35 Charles Street, Mayfair To Register: http://www.proactiveinvestors.co.uk/register/event_details/119 OUTLOOK We look forward to announcing the commencement of the Phase I trial of PXS-5382A (LOXL2 inhibitor), which is directed to the very major conditions such as IPF and NASH, where fibrosis is a significant cause of morbidity and mortality. Synairgen will progress PXS-5382A through the Phase I trial, the results of which are expected mid-2018. Thereafter Synairgen and Pharmaxis plan to out-license PXS- 5382A to a suitable partner to fully realise the commercial value of this compound given the potential size and number of indications it could address. We are excited about progressing the development of SNG001 into COPD, with a Phase II trial in targeted �at risk� patients in the final stages of preparation. In parallel, we are considering optimal financing strategies to enable us to progress this exciting development over the medium term

http://www.proactiveinvestors.co.uk/companies/stocktube/8163/synairgen-planning-winter-trial-as-it-develops-inhaled-interferon-beta-drug-for-copd-8163.html

With a current market Cap of around �13m, Blue Chip Major shareholders and Two major programmes underway.. This must be one of the most underated Pharma Stocks on the AIM market... Todays news demonstrates how the SNG team led by Richard Marsden really have created two very signifcant opportunities .. Interferon B and LOXL2... LOXL2 has Pharmaxis as SNG;s Partner .. and I suspect that a Partner is being lined up for Interferon B and its Phase 2B trial for COPD... With limited shares in circulation and with recent additional purchases by Richard Griffiths taking his holding to over 12.7 Million shares ... The shares should be a stonking buy... There is no debt on the books of SNG .. the result of great financial controls .. and with 100% of IFN-β (SNG001) it should not be too difficult to find a partner willing to take a stake in Interferon B to persue / complete Phase 2 B trials..Thus in my opinion reducing the chances of the need to raise further funds.. The opportunities for both Programmes are in my opinion ' Very Signicant' in creating real shareholder value... multiples I believe of its current share price.. I suspect that SNG will not remain invisible to the wider market for much longer...

http://www.proactiveinvestors.co.uk/companies/stocktube/8079/quantum-pharma-acquisition-the-logical-next-step-in-growth-story-for-clinigen-8079.html Zacks Investment Research cut shares of Clinigen Group Plc (NASDAQ:CLIGF) from a buy rating to a hold rating in a research note issued to investors on Friday, September 8th

The issues we shareholders in QP face ... are Clinigen share Price Volitility, 10% approx off their peak price of 1149p..What has driven this and other shares lower is BOE threatening to raise interest rates etc, Pound / dollar rate etc... This volitility will remain I believe until the Budget in November...then who knows what might happen... The 82p price whilst disappointing was I suspect the lowest price the instituions would accept for their holdings ... A la Henderson .. These irrecvocable commitments to Clinigen really stop any other bidder entering the frame unless it was a quick substantially higher value than 82p and in cash.. This is a very unlikely scenario..An alternative bidder would I believe already raised their heads by now and none have.. We are therefore linked to the performance of Clinigen shares which as as stated are already 10% below their peak... and this is before any small shareholder sell off when QP shares are converteed.. Listened to the MD of Clinigen on Proactive Investor talking about the QP acquisition... On a personal note he sounded very much like the Ex QP CEO Andrew Scaife (Just my opinion) .. He did mention that Chris Rigg would be joining the Management team of Clinigen ( this might have helped slightly persuade him to support the Clinigen offer- only joking he would never do that ) He will be able to cash in his Options (6 million I think at the last count and will receive both substantial cash and shares from his new employer.. What are the options... Sell up now and get 77p ish per share cash or if you are a believer in Clinigens future then let the offer run and take your cash and shares...It was the Andrew Scaife look alike / sound bites ( a very personal gut feel only) that stops me remaining on the Clinigen Bus journey.. Good Luck all.

has increased his stake in SNG from 11.09% to 13.95% an additional (approx) 2.6 million shares ... A big vote of confidence in the SNG portfolio..

The consideration payable under the Acquisition represents a premium of approximately: -- 23.5 per cent. to the Closing Price per Quantum Share of 66.38 pence on 12 September 2017 (being the last Business Day prior to the publication of this Announcement); -- 26.2 per cent. to the Closing Price per Quantum Share of 65.00 pence on 15 August 2017 (being the Business Day prior to the commencement of the Offer Period; -- 46.1 per cent. to Quantum's average share price of 56.12 pence in the three months prior to the commencement of the Offer Period; and -- 64.7 per cent. to Quantum's average share price of 49.79 pence in the six months prior to the commencement of the Offer Period.

What I find odd in this potential takeover scenario... Is the fact that Clinigen appear to me to be starting from a near minimal holding in its target QP... I could understand a full bid being made if they held 29.9% of their target (QP) and then launched a bid for the remaining equity... Without this platform for a full bid... the only sense I make of this is that the offer price for QP would have to be at a price that would (in my opinion be a knockout Price) ensuring that there are no substantial shareholders or groups of shareholders that would stop a full exceptance by 90% of the equity... They can compulsary acquire the remaning 10% if this figure is achieved... Will it be a knockout price with full support of the board and major shareholders or a damp quid bid leading to rejection? What I also find interesting are the costs expended by Clinigen in this possible takeover proposal.. What does worry me is the opening of the books to Clinigen... and their (now) awareness of our pipeline, cost structure and growth potential.. We will know on the 13 th the outcome !

From the ADVFN BB... https://www.youtube.com/watch?v=6uIXJ22ESb4 Pharmaxis on LOXL - well worth watching

All positions over 1 % have to be declared during the bidding process / timescales... hence Andrews declaration.. The figures quoted on Form 8.3 is his beneficial holding.. which he appears to have kept even after leaving QP.